Comparative efficacy of 5-hydroxytryptamine-3 (5-HT3) receptor antagonists with or without dexamethasone for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy (HEC): a network meta-analysis
PeerJ · 02.04.2026 · 14 · e21047
DOI: 10.7717/peerj.21047 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift PeerJ, online erschienen am 02.04.2026. Verfasst von Hongxia Xu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacy, Wendeng Hospital of Traditional Chinese Orthopedics and Traumatology of Shandong Province, Wendeng District, Weihai …. Hauptthemen laut MEDLINE: Serotonin 5-HT3 Receptor Antagonists, Dexamethasone, Nausea, Vomiting. Die Arbeit nennt 77 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: 2021 Clinical Research Funds of Shandong Medical Association-Qilu Specialized Funding.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Objective
This network meta-analysis evaluated the efficacy of 5-hydroxytryptamine-3 (5-HT3) receptor antagonists, with or without Dexamethasone (D), for preventing chemotherapy-induced nausea and vomiting (CINV) in patients undergoing highly emetogenic chemotherapy (HEC) who were limited to these regimens.
Methods
Randomized controlled studies (RCTs) were searched in PubMed, Embase, Cochrane and Web of Science from their inception up to January 28, 2026 (a supplementary search was conducted from April 1, 2025, to January 28, 2026), to identify studies on patients who used 5-HT3 receptor antagonists (with or without Dexamethasone) to prevent nausea and vomiting caused by highly emetogenic chemotherapy. A total of 36 randomized controlled trials (reported in 37 articles) enrolling 11,131 patients were included in this analysis. The outcome measures included acute nausea, acute vomiting, acute complete control, delayed nausea, delayed vomiting and delayed complete control.
Results
Palonosetron (P) is generally more effective than first-generation 5-HT3 receptor antagonists (1 st 5-HT3 antagonists), with a significantly greater advantage over Ondansetron in the delayed phase (such as in delayed vomiting (20 trials/6,347 patients) (RR 1.47, 95% CI [1.03–2.08]). In all phases, adding Dexamethasone to 1 st 5-HT3 antagonists significantly improved efficacy compared to using them alone. However, combining Dexamethasone with palonosetron showed no significant advantage over Palonosetron alone in any outcome measure in indirect comparisons. In the delayed phase [such as in delayed vomiting (20 trials/6,347 patients)), Palonosetron + Dexamethasone (P+D) demonstrated statistically significant superiority over both Ondansetron + Dexamethasone (O+D) (RR 1.35, 95% CI [1.14–1.60]) and Granisetron + Dexamethasone (G+D) (RR 1.52, 95% CI [1.22–1.91]). However, in the acute phase, Palonosetron + Dexamethasone showed statistically significant superiority over Ondansetron + Dexamethasone (RR 0.81, 95% CI [0.69–0.96]) only in preventing acute vomiting (23 trials/9096 patients). In contrast, no significant efficacy differences were observed between Palonosetron + Dexamethasone and Tropisetron + Dexamethasone (T+D), or Ramosetron + Dexamethasone (R+D). No significant differences were observed between Palonosetron and 1 st 5-HT3 antagonists + Dexamethasone.
Conclusions
Dexamethasone may enhance the efficacy of first-generation 5-HT 3 receptor antagonists, but may not provide a similar benefit for Palonosetron. Palonosetron is generally more effective than first-generation 5-HT3 antagonists. Palonosetron + Dexamethasone demonstrates superior efficacy over Ondansetron + Dexamethasone or Granisetron + Dexamethasone, particularly in the delayed phase. Further studies are needed between Palonosetron + Dexamethasone and Tropisetron + Dexamethasone or Ramosetron + Dexamethasone, as well as between Palonosetron monotherapy and 1 st 5-HT3 antagonists + Dexamethasone.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Pharmacy, Wendeng Hospital of Traditional Chinese Orthopedics and Traumatology of Shandong Province, Wendeng District, Weihai City, Shandong Province, China.
- Rehabilitation Department, Wendeng Hospital of Traditional Chinese Orthopedics and Traumatology of Shandong Province, Wendeng District, Weihai City, Shandong Province, China.
- Department of Anesthesiology, Wendeng Hospital of Traditional Chinese Orthopedics and Traumatology of Shandong Province, Wendeng District, Weihai City, Shandong Province, China.
Förderung
- 2021 Clinical Research Funds of Shandong Medical Association-Qilu Specialized Funding
Zitieren
APA
Xu, H., Xing, J., Yang, S., Rong, L., Liu, L., & Chen, X. (2026). Comparative efficacy of 5-hydroxytryptamine-3 (5-HT3) receptor antagonists with or without dexamethasone for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy (HEC): a network meta-analysis. PeerJ, 14, e21047. https://doi.org/10.7717/peerj.21047
Vancouver
Xu H, Xing J, Yang S, Rong L, Liu L, Chen X. Comparative efficacy of 5-hydroxytryptamine-3 (5-HT3) receptor antagonists with or without dexamethasone for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy (HEC): a network meta-analysis. PeerJ. 2026;14:e21047. doi:10.7717/peerj.21047
BibTeX
@article{Xu2026,
author = {Xu, Hongxia and Xing, Jiankun and Yang, Shaohui and Rong, Lingyan and Liu, Lingyan and Chen, Xiaotao},
title = {Comparative efficacy of 5-hydroxytryptamine-3 (5-HT3) receptor antagonists with or without dexamethasone for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy (HEC): a network meta-analysis},
journal = {PeerJ},
year = {2026},
volume = {14},
pages = {e21047},
doi = {10.7717/peerj.21047}
}
EUVIMED